Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg shrugs off Hilton Food's seafood woes, stays at 'buy'

(Sharecast News) - Berenberg has maintained a positive view on Hilton Food Group despite a steep sell-off of the stock last week due to seafood-related supply issues, highlighting the strong momentum in other parts of the business.

The broker kept a 'buy' recommendation, and trimmed its target price for the shares from 1,120p to 1,100p - which still represents significant upside to the current share price of around 667p.

Interim results from the proteins-focused food packaging company on 3 September caused a sell-off in the shares after it cited supply chain problems related to smoked salmon shipments to the US and inflationary trends in white fish market.

Shares dropped 17% on the day and remain down 19% since the day before the results.

"The issues with the seafood business affecting the H1 2025 results are not the same as the issues that resulted in a profit warning in August 2022. Despite the differences, the market has treated them as being the same, in our view," Berenberg said.

Nevertheless, the company still delivered first-half results ahead of consensus forecasts, supported by a strong performance from the retail meat business, which delivered volume growth across the board and outperformed the wider sector.

"We think the strong trading momentum in the retail meat business (which accounts for 80% of group sales), reflected in the delivery of sales volume growth ahead of the market, is being overlooked at current valuation levels," Berenberg said.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.